Cambio - Excellence in Molecular Biology

Oligo Synthesis

Oligo Synthesis : Supports, CPGs

Prices quoted are for single packs only. For multiples of the same product please request a quote. Some of Glen's products are hazardous and may be subject to additional shipping charges. Full product information is available on Glen Research's website.



Glen Research

Catalogue No.DescriptionPack SizePriceQty
20-2903-013'-CPR II CPG 0.1g £64.00 Quantity Add to Order
20-2903-103'-CPR II CPG 1.0g £436.00 Quantity Add to Order
20-2903-133'-CPR II CPG 1x10µm £164.00 Quantity Add to Order
20-2903-143'-CPR II CPG 1x15µm £255.00 Quantity Add to Order
20-2903-413'-CPR II CPG 4x1.0µm £91.00 Quantity Add to Order
20-2903-423'-CPR II CPG 4x0.2µm £55.00 Quantity Add to Order




Catalog Number: 20-2903-xx

Description: 3'-CPR II CPG

1-O-succinoyl-long chain alkylamino-CPG

F.W.: 79.98

Diluent: Not Applicable
Coupling: This support should be used in a manner identical to normal protected nucleoside support since it contains the DMT group.
Deprotection: No changes needed from standard method recommended by synthesizer manufacturer. Technical Bulletin
Storage: Controlled room temperature or lower, dry
Stability in Solution: Not Applicable
Please Note: Chemical Phosphorylation Reagent II is covered by US Patent No.: 5,959,090 and European Patent: EP0816368


Chemical Phosphorylation Reagent is most commonly used to phosphorylate the 5’-terminus of an oligonucleotide. Although this product is also successful in 3’-phosphorylation, 3’-Phosphate CPG allows direct preparation of oligonucleotides with a 3’-phosphate group. Chemical Phosphorylation Reagent II contains a DMT group on a side chain which is stable to base cleavage and can be left on the oligonucleotide for use in RP purification. The DMT group is later removed with aqueous acid and the side chain is eliminated after brief treatment with aqueous ammonium hydroxide to yield the 5’-phosphate.1 Solid CPR II is similar in performance to CPR II but it is easier to prepare aliquots since it is a powder. Many researchers treat synthesis supports with a hindered base (e.g., diethylamine, diisopropylethylamine, or DBU) post-synthesis to eliminate and remove the cyanoethyl phosphate groups. In this way, the acrylonitrile formed in situ is removed from the support and is not available to alkylate dT residues at the N3 position in the oligos. Since the sulfonylethyl group in 3’-Phosphate CPG is also susceptible to ß-elimination leading to oligo cleavage, this technique is not compatible with 3’-phosphate CPG. Using CPR II CPG, which is base labile but does not support ß-elimination, the cyanoethyl groups can be removed from the oligo prior to cleavage and base deprotection. ABI-style vials and columns are supplied unless otherwise requested.

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200



Glen Report 21.1

Glen Report 23.1

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200

Related products

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200